Payment & Shipping Terms:
|MW:||592.7488||Boiling Point:||744.4±70.0 °C(Predicted)|
|Density:||1.28±0.1 G/cm3(Predicted)||Acidity Coefficient (pKa):||7.06±0.50(Predicted)|
|Color:||White Color Powder|
Focal segmental glomerulosclerosis (FSGS) is a common glomerular disease, and patients often show varying degrees of proteinuria and nephrotic syndrome. Its incidence is increasing, and approximately 50% of patients with primary FSGS and nephropathy-range proteinuria in the United States require RRT for 5-10 years after diagnosis. FSGS has a poor prognosis and is a common cause of end-stage renal disease (ESRD) in adults (5%) and children (12%).
Currently the main treatments are corticosteroids and other immunosuppressants, which are designed to reduce proteinuria, an independent predictor of kidney survival in patients with primary FSGS. These drugs are usually used in combination with renin-angiotensin system inhibitors (RASIs), but side effects caused by immunosuppressants often limit their clinical application. Therefore, there is an urgent need for drugs that can effectively and safely relieve FSGS proteinuria and are well tolerated.
Studies have shown that endothelin (ET) and angiotensin II can damage podocytes through various molecular mechanisms, and endothelin receptor antagonists (ERAs) and RASIs can improve parenchymal damage and reduce proteinuria.
Sparsentan is a drug that blocks both the angiotensin II and endothelin 1 receptors. To determine its effectiveness and safety in the treatment of FSGS, the Howard Trachtman research team from New York University conducted a double-blind, randomized controlled trial . The findings are published in the JASN journal.
Contact Person: Ma